1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Acrux Limited

Acrux Limited

ARUXF
Acrux LimitedUS flagOther OTC
0.02
USD
+0.00
- -
6.94MMarket Cap
Acrux Limited
ARUXF
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.34
0.54
0.05
0.09
0.32
0.15
0.17
0.14
0.02
- -
0.01
0.01
0.01
0.03
0.02
- -
Revenue per Share
0.29
0.35
0.04
0.04
0.17
0.07
0.08
- -
-0.09
-0.05
-0.06
-0.06
-0.03
- -
-0.02
-0.02
Basic EPS, GAAP
0.3
0.39
-0.02
0.04
0.22
0.06
0.1
0.03
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
0.6
- -
0.08
0.2
0.08
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.49
0.28
0.32
0.28
0.25
0.24
0.25
0.26
0.18
0.13
0.07
0.05
- -
- -
-0.02
-0.02
Book Value per Share
0.36
0.27
0.32
0.28
0.25
0.12
0.15
0.22
0.18
0.13
0.07
0.08
0.03
0.03
0.01
- -
Tangible Book Value per Share
160
165
166
167
167
167
167
167
167
167
168
220
284
286
289
352
Basic Weighted Avg Shares
55
90
9
16
53
25
28
23
3
1
1
1
2
8
5
1
Sales/Revenue/Turnover
90
92.98
37.16
60.86
87
68.71
68.92
45.31
-408.67
-2,058.64
-963.85
-1,215.48
-754.28
-40.22
-168.43
-753.95
Operating Margin (%)
- -
- -
- -
1
1
1
1
2
1
- -
1
1
1
1
1
- -
Depreciation Expense
47
57
7
7
28
11
13
- -
-14
-8
-9
-13
-10
-1
-6
-6
Net Income, GAAP
5.32
30.74
- -
31.02
36.22
33.77
28.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
84.79
63.78
84.02
44.54
52.41
45.21
46.35
-1.04
-527.8
-1,319.33
-755.87
-944.58
-572.08
-9.06
-113.93
-499.58
Profit Margin (%)
57
26
32
26
25
25
28
36
26
19
10
16
7
8
2
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
2
2
2
LT Debt
80
46
53
47
42
41
44
44
30
22
13
18
9
9
3
1
Total Equity
83.77
87.53
- -
12.79
62.33
25.18
30.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
86.47
92.09
- -
13.87
63.44
27.53
31.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
86.47
92.09
14.96
13.87
63.44
27.53
31.71
-0.57
-39.34
-32.85
-56.44
-111.81
-176.17
-123.52
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-23.44%
-28.49%
-68.77%
Free Cash Flow
12.96%
50.95%
-98.19%
Net Income, GAAP
620.41%
116.13%
2.5%
Sales/Revenue/Turnover
24%
61.88%
-76.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
8
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
tella, Inc. (2191.T)
Stealth BioTherapeutics Corp (MITO)
OSR Holdings, Inc. (OSRH)
Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
UCB S.A. (UCBJY)
Cyclerion Therapeutics, Inc. (CYCN)
Business
Acrux Limited (ASX:ACR; OTC:ARUXF) develops, registers and commercializes topically applied generic pharmaceutical products, with a primary focus on the US market through FDA-approved Abbreviated New Drug Applications (ANDAs); core offerings include Prilocaine 2.5% and Lidocaine 2.5% Cream, a topical anesthetic; Evamist, an estradiol spray for menopause symptoms; Dapsone 5% Gel and Dapsone 7.5% Gel, treatments for acne vulgaris; Nitroglycerin 0.4% Ointment for chronic anal fissure pain; and a pipeline of 16 products at stages from formulation development to commercialization, targeting conditions such as fungal toenail infections and cold sores. The company, founded in 1998 and headquartered at 103-113 Stanley Street, West Melbourne, Australia, operates principally in Australia and the United States, leveraging on-site laboratories and GMP manufacturing. Recent developments encompass FDA approvals for Dapsone 7.5% Gel in August 2024 and Nitroglycerin 0.4% Ointment in December 2024, with partner-led launches of Nitroglycerin in December 2024 and planned Dapsone 7.5% rollout in fiscal 2025; a $4.0 million capital raise via placement and share purchase plan in December 2024, including attaching options exercisable at 5.25 cents through February 2027; receipt of $2.975 million in R&D tax incentives for fiscal 2024; introduction of a 90mg pack for Dapsone 5% Gel in December 2024; and announcement in February 2025 of CEO Michael Kotsanis' planned retirement pending successor appointment.